| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1376647 | Bioorganic & Medicinal Chemistry Letters | 2008 | 6 Pages |
Abstract
5-Hydroxy-3(2H)-pyridazinone derivatives were investigated as potent inhibitors of genotype 1 HCV NS5B polymerase focusing on the optimization of their drug metabolism and pharmacokinetics (DMPK) profiles. This investigation led to the discovery of potent inhibitors with improved DMPK properties.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
![Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties](/preview/png/1376647.png "First Page Preview: Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties")
Authors
Maria V. Sergeeva, Yuefen Zhou, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Ellen Okamoto, Leo Kirkovsky, Ruhi Kamran, Laurie A. LeBrun, Mei Tsan, Rupal Patel, Amit M. Shah, Matthew Lardy, Alberto Gobbi, Lian-Sheng Li, Jingjing Zhao,